Medable trots its way to unicorn status amid virtual trial craze. Is a public debut next?
As it becomes apparent that decentralized clinical trials will likely be a part of drugmakers’ strategies long after the pandemic is over, a tech developer is galloping its way to unicorn status with a $304 million megaround.
Medable unveiled a hefty Series D round on Tuesday — its fourth in the last year and a half — led by Blackstone Growth, Tiger Global and GSR Ventures. The new cash brings the Palo Alto-based company’s total raise to $521 million, with a whopping $2.1 billion valuation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.